Want to see INTS full AI Analyst Report?
Top Page
Intensity Therapeutics, Inc.
(NASDAQ:INTS)
Select Model
Select Model
Rating:47Neutral
Price Target:
$4.50
▼(-18.18% Downside)
Action:Reiterated
Date:07/08/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and continued cash burn), partially offset by a low-debt balance sheet. Technicals are mixed (near-term strength vs. longer-term downtrend), while valuation is limited by a negative P/E and no dividend data; corporate events were modestly positive but include potential dilution from expanded equity plans.
Positive Factors
Specialized intratumoral oncology pipeline
The company is a clinical-stage oncology biotech focused on intratumoral and locoregional therapeutics with lead program INT230-6 combining chemo plus an excipient to enhance tumor delivery. This focused modality creates a durable strategic niche and potential clinical differentiation versus systemic therapies.
Negative Factors
Pre-revenue with sustained net losses
INTS remains a pre-revenue company with no commercial sales and a sizable trailing-twelve-month net loss (~-$10.7M). Without a revenue base, ongoing operations and pipeline advancement depend on financing or partnerships, making operational sustainability and program continuity contingent on external capital availability.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized intratumoral oncology pipeline
The company is a clinical-stage oncology biotech focused on intratumoral and locoregional therapeutics with lead program INT230-6 combining chemo plus an excipient to enhance tumor delivery. This focused modality creates a durable strategic niche and potential clinical differentiation versus systemic therapies.
Read all positive factors
Intensity Therapeutics, Inc. (INTS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.84M
Dividend YieldN/A
Average Volume (3M)53.43K
Price to Earnings (P/E)―
Beta (1Y)0.39
Revenue GrowthN/A
EPS Growth73.15%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.97
Shares Outstanding2,702,820
10 Day Avg. Volume39,907
30 Day Avg. Volume53,429
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)11.72
Price to Sales (P/S)0.00
P/FCF Ratio-15.07
Enterprise Value/Market Cap-0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit458.87
Enterprise Value/Ebitda0.40
Forecast
1Y Price Target
$30.00Price Target Upside445.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.68
Revenue Forecast (FY)N/A
Intensity Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, ...
How the Company Makes Money
null...
Intensity Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -7.00K | -26.00K | 0.00 | -147.00K | 0.00 | 0.00 |
| EBITDA | -7.95M | -11.61M | -16.27M | -10.09M | -7.32M | -7.88M |
| Net Income | -10.69M | -11.61M | -16.27M | -10.54M | -7.58M | -7.90M |
Balance Sheet | ||||||
| Total Assets | 12.29M | 14.10M | 4.78M | 17.30M | 1.76M | 5.22M |
| Cash, Cash Equivalents and Short-Term Investments | 10.24M | 11.92M | 2.59M | 14.78M | 1.31M | 4.54M |
| Total Debt | 102.00K | 110.00K | 138.00K | 158.00K | 4.49M | 2.34M |
| Total Liabilities | 2.31M | 2.23M | 1.86M | 4.13M | 16.86M | 13.90M |
| Stockholders Equity | 9.98M | 11.88M | 2.92M | 13.16M | -15.10M | -8.68M |
Cash Flow | ||||||
| Free Cash Flow | -9.07M | -9.23M | -15.22M | -7.21M | -5.48M | -6.83M |
| Operating Cash Flow | -9.07M | -9.23M | -15.22M | -7.21M | -5.48M | -6.83M |
| Investing Cash Flow | 0.00 | 0.00 | 6.35M | -6.02M | 0.00 | 0.00 |
| Financing Cash Flow | 18.39M | 18.56M | 2.90M | 20.47M | 2.25M | 2.05M |
Intensity Therapeutics, Inc. Technical Analysis
Negative
5.50
Price Trends
4.39
Positive
5.25
Negative
7.50
Negative
Market Momentum
0.16
Negative
57.25
Neutral
53.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INTS, the sentiment is Negative. The current price of 5.5 is above the 20-day moving average (MA) of 4.48, above the 50-day MA of 4.39, and below the 200-day MA of 7.50, indicating a neutral trend. The MACD of 0.16 indicates Negative momentum. The RSI at 57.25 is Neutral, neither overbought nor oversold. The STOCH value of 53.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INTS.
Intensity Therapeutics, Inc. Risk Analysis
Intensity Therapeutics, Inc. disclosed 62 risk factors in its most recent earnings report. Intensity Therapeutics, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Intensity Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $12.84M | -0.67 | -136.82% | ― | ― | 73.15% | |
43 Neutral | $961.98K | >-0.01 | -63.03% | ― | ― | 88.07% | |
42 Neutral | $989.16K | ― | ― | ― | -1.80% | -198.00% | |
| ― | $2.48M | -0.09 | -168.95% | ― | ― | 84.00% |
* Healthcare Sector Average
INTS
Intensity Therapeutics, Inc.
4.70
-3.26
-40.95%
BDRX
Biodexa Pharmaceuticals
2.13
-40.39
-94.99%
QCLS
Q/C Technologies
3.45
-9.49
-73.34%
SCNI
Scinai Immunotherapeutics
0.25
-1.96
-88.86%
OGEN
Oragenics
0.54
-0.78
-59.02%
Intensity Therapeutics, Inc. Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Intensity Therapeutics Stockholders Approve Proposals at Annual Meeting
Positive
Jun 16, 2026
On June 16, 2026, Intensity Therapeutics, Inc. held its annual meeting of stockholders via live webcast, with about 40.74% of eligible common shares represented, constituting a quorum. Stockholders elected two Class III directors, Dr. Emer Leahy a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.